Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ph14050435 http://scihub22266oqcxt.onion/10.3390/ph14050435 34066399!8148206!34066399     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\34066399.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Pharmaceuticals+(Basel) 2021 ; 14 (5): ä Nephropedia Template TP {{tp|p=34066399|t=2021. Targeting Energy Expenditure-Drugs for Obesity Treatment |pdf=|usr=}}{{34066399}} gab.com Text Targeting Energy Expenditure-Drugs for Obesity Treatment JO: Pharmaceuticals (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=34066399 #FOAvip Obesity and overweight are associated with lethal diseases. In this context, obese and overweight individuals infected by COVID-19 are at greater risk of dying. Obesity is treated by three main pharmaceutical approaches, namely suppressing appetite, reducing energy intake by impairing absorption, and increasing energy expenditure. Most compounds used for the latter were first envisaged for other medical uses. However, several candidates are now being developed explicitly for targeting obesity by increasing energy expenditure. This review analyzes the compounds that show anti-obesity activity exerted through the energy expenditure pathway. They are classified on the basis of their development status: FDA-approved, Withdrawn, Clinical Trials, and Under Development. The chemical nature, target, mechanisms of action, and description of the current stage of development are described for each one. Twit Text FOAVip Targeting Energy Expenditure-Drugs for Obesity Treatment ????Pharmaceuticals (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=34066399 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34066399 #FOAvip English Wikipedia <ref>{{Cite pmid|34066399}}</ref> Targeting Energy Expenditure-Drugs for Obesity Treatment #MMPMID34066399 Jimenez-Munoz CM; Lopez M; Albericio F; Makowski K Pharmaceuticals (Basel) 2021[May]; 14 (5): ä PMID34066399show ga Obesity and overweight are associated with lethal diseases. In this context, obese and overweight individuals infected by COVID-19 are at greater risk of dying. Obesity is treated by three main pharmaceutical approaches, namely suppressing appetite, reducing energy intake by impairing absorption, and increasing energy expenditure. Most compounds used for the latter were first envisaged for other medical uses. However, several candidates are now being developed explicitly for targeting obesity by increasing energy expenditure. This review analyzes the compounds that show anti-obesity activity exerted through the energy expenditure pathway. They are classified on the basis of their development status: FDA-approved, Withdrawn, Clinical Trials, and Under Development. The chemical nature, target, mechanisms of action, and description of the current stage of development are described for each one. äTargeting Energy Expenditure-Drugs for Obesity Treatment (epmc).pdf DeepDyve Pubget Overpricing